Pfizer signs companion diagnostic deal for cancer vaccine candidate
This article was originally published in Scrip
Executive Summary
Pfizer and DxS, a subsidiary of Qiagen, are to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in Phase II testing for the treatment of the brain cancer glioblastoma multiforme.